Coordination complex is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-30. Numbers and descriptions here follow the published literature rather than marketing material.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
GHK-Cu is a coordination complex formed from the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, the terminal amino group, and the deprotonated amide nitrogen. This arrangement creates a square-planar or distorted geometry around the metal center, depending on pH and the presence of competing ligands. The complex occurs naturally in human plasma, saliva, and urine at low concentrations, and its sequence is conserved across many vertebrate species.
Discovery of GHK is generally attributed to work in the 1970s that isolated a plasma factor influencing liver cell behavior. Subsequent studies identified the copper-binding tripeptide and its ability to chelate copper with high affinity. Early reports linked the complex to wound healing and tissue remodeling in animal models. The free peptide and the copper-bound form have different properties, so the two are distinguished in the literature. Whether endogenous GHK-Cu serves a single primary physiological role remains an open question.
The molecular weight and charge of GHK-Cu depend on the pH and the number of coordinated ligands. At neutral pH, the peptide typically binds one copper ion, but ternary complexes with other biomolecules can form. Spectroscopic methods such as electron paramagnetic resonance and circular dichroism are used to study the coordination environment. Reports on the exact geometry vary because the complex is dynamic in solution. Researchers often use synthetic GHK-Cu rather than extracted material to control stoichiometry and purity.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper-binding tripeptide complex | Includes Gly-His-Lys and Cu(II) |
| Molecular formula | C14H22CuN6O4 | Reported for the 1:1 complex |
| Appearance | Blue to blue-violet solid | Color arises from copper d-d transitions |
| Solubility class | Water-soluble; slightly soluble in polar organic solvents | Often prepared as aqueous stock |
| Typical storage | -20 °C, desiccated, protected from light | Limits oxidation and moisture uptake |
Laboratory characterization of GHK-Cu typically combines separation, spectroscopic, and elemental techniques. Reverse-phase high-performance liquid chromatography is widely used to assess peptide purity, often with ultraviolet detection near the copper-related absorption band or with mass spectrometry for identity confirmation. Because the molecule contains copper, elemental methods such as inductively coupled plasma mass spectrometry or atomic absorption spectroscopy are used to quantify metal content and confirm stoichiometry. No single universal pharmacopeial monograph exists for GHK-Cu. Laboratories therefore validate their own methods, and reported purity values depend on the chosen assay and calibration standards.
Stability of GHK-Cu is influenced by light, oxygen, moisture, pH, and temperature. Solid material is generally kept desiccated and frozen to reduce hydrolysis and oxidation, while aqueous solutions are best prepared fresh or stored cold in aliquots. Repeated freeze-thaw cycles can promote aggregation, precipitation, or peptide degradation. Copper coordination may change under strongly acidic or alkaline conditions, potentially altering the complex's spectroscopic properties. Published long-term stability data for specific matrices, such as cosmetic emulsions or biological buffers, are limited, so shelf-life claims should be treated as formulation-specific rather than universal.
Characterizing GHK-Cu requires methods that distinguish the intact complex from free peptide and unbound copper. UV-visible absorption around 600 nm provides a rapid check for copper coordination, while circular dichroism reports on peptide secondary structure. Mass spectrometry confirms the peptide mass and can detect copper adducts under carefully controlled conditions. Electron paramagnetic resonance is particularly informative for Cu(II) because it reveals the ligand field symmetry. No single technique fully defines the complex, so laboratories combine orthogonal methods.
Stability of GHK-Cu in solution depends on pH, temperature, buffer composition, and oxygen exposure. The copper center can undergo reduction or dissociation, especially in the presence of strong metal chelators such as EDTA. Aqueous solutions are often prepared fresh or stored frozen to limit degradation. Lyophilized solid is more stable than liquid formulations, but it can absorb moisture and should be kept dry. Light exposure may also affect copper complexes, though the effect is often modest.
==== Borderline personality disorder ==== Similar epigenetic alterations in OPRK1 methylation patterns have been linked to borderline personality disorder (BPD), where an imbalance between opioid receptor systems could cause symptoms such as chronic dysphoria, suicidality, and emotional instability. In individuals with BPD, decreased DNA methylation (hypomethylation) in a differentially methylated region (DMR) located within the promoter region, specifically at a cluster of five adjacent CpG sites (CG34–CG38) positioned immediately upstream of core CpG islands (CGI-1 and CGI-2), results in enhanced gene transcription and elevated KOR expression. The DMR hypomethylation in BPD is strategically positioned on the "falling slope" of the gene's methylation gap; a transition zone between the sparsely methylated CpG island promoter and densely methylated downstream regions. This location amplifies the functional consequences of hypomethylation by progressively steepening the methylation gradient, further facilitating transcription initiation at multiple transcription start sites (TSS) distributed throughout the CGI promoter region. Consequently, the decreased methylation rates in the DMR are associated with increased OPRK1 mRNA transcription and heightened KOR protein expression in peripheral white blood cells and, by extension, in central brain regions involved in emotion regulation. Symptom severity in BPD correlates with DMR hypomethylation levels.
Susineridine (INNTooltip International Nonproprietary Name; developmental code name YZJ-4729) is an atypical μ-opioid receptor (MOR) agonist and opioid analgesic which is under development for the treatment of postoperative pain. It is given intravenously. The drug acts as a selective biased partial agonist of the MOR, with functional selectivity for activation of G protein signaling over β-arrestin2 recruitment. Its mechanism of action and pharmacological activity are said to be similar to those of oliceridine. However, in-vitro findings suggest that susineridine may have a greater degree of G protein bias than oliceridine. The drug produces analgesic effects in multiple animal models of pain and produces less respiratory depression than morphine or oliceridine. The pharmacokinetics of susineridine in humans have been studied. Susineridine was patented and first described in the scientific literature in 2023. It is under development by Shanghai Haiyan Pharmaceutical Technology in China. As of May 2025, the drug is in phase 3 clinical trials for postoperative pain.
Kynureninase or L-Kynurenine hydrolase (KYNU) (EC 3.7.1.3) is a pyridoxal-phosphate dependent enzyme that catalyses the cleavage of kynurenine into anthranilic acid. It can also act on 3-hydroxykynurenine (to produce 3-hydroxyanthranilate) and some other (3-arylcarbonyl)-alanines. Humans express one kynureninase enzyme that is encoded by the KYNU gene located on chromosome 2. KYNU is part of the pathway for the catabolism of tryptophan and the biosynthesis of nicotinamide adenine dinucleotide (NAD) cofactors from tryptophan (Trp). This reaction produces anthranilic acid and L-alanine:
Sources: en.wikipedia.org
== Genomic location and tissue expression == The ABCC1 gene, the gene that encodes the ABCC1 protein, is found on chromosome 16 within the nucleus. The protein resides intracellularly on the basolateral side of the plasma membrane which differs from other ATP-binding cassette transporters that are found on the apical side of the membrane. While ABCC1 is generally found throughout most tissues in humans, it is particularly prevalent in the lungs, spleen, testes, kidneys, placenta, thyroid, bladder, and adrenal glands. It is also found in the endothelium cells of the blood-brain barrier.
However, after a specific amount of time (within 3 days according to a study conducted at the University of Rochester), the cells in blind mole rats release interferon-beta (which the immune system normally uses to counter viruses) in response to over-proliferation of cells caused by the suppression of apoptosis. In this case, the interferon-beta triggers cells to undergo necrosis, and this mechanism also kills cancer cells in blind mole rats. Because of tumor suppression mechanisms such as this, blind mole rats and other spalacids are resistant to cancer.
Birmans have a medium-sized, rectangular body with a broad face and distinct Roman nose. Their ears are ideally as wide on the base as they are tall and should be set as much on top of the head as on the side. The eyes are rounded and should be a deep sapphire blue. The Birman's fur is medium-long and should have a silky texture. Unlike a Persian or Himalayan, they have no undercoat, thus are much less prone to matting. Coat colour is always pointed, save for the contrasting pure white, symmetrical "gloves" on each paw that are the trademark of the breed. The white must involve all toes and in front must stop at the articulation or at the transition of toes to metacarpals. These gloves should extend noticeably further up the back of the leg (referred to as the "laces"), finishing with an inverted V extended half to three-fourths up the hock. Any other spot of white on the points is considered a serious fault. The base body colour is white to cream, with a wash of colour that corresponds to the points, but is much paler. Recognized point colours are seal, chocolate, red and the corresponding dilute varieties: blue, lilac and cream. Tabby and tortie variations in seal, chocolate, blue or lilac are also allowed; other colours are in development.
Sources: en.wikipedia.org
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide binds copper through its histidine residue and neighboring amide nitrogens, forming a stable coordination compound. It is studied as a research chemical and used in some cosmetic formulations.
Yes, the peptide and its copper complex have been detected in human plasma, saliva, and urine. Endogenous concentrations are low, and reported levels change with age and physiological state. The biological significance of those changes is still an active area of study.
GHK refers to the free tripeptide without a bound copper ion. GHK-Cu contains copper(II) coordinated to the same peptide backbone. The presence of copper affects the complex's color, stability, and interaction with biological molecules.
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide coordinates the metal through its histidine imidazole, terminal amino group, and amide nitrogen. It is studied in biochemistry and dermatological research.